Splicing factor TRA2B enhances synthesis of androgen receptor variant AR-V7 in prostate cancer cells
Authors:
- Nicholas BrittainNBNicholas Brittain
- Alec PaschalisAPAlec Paschalis
- Ryan NelsonRNRyan Nelson
- Beth AdamsonBABeth Adamson
- Laura WalkerLWLaura Walker
- Ruaridh DuncanRDRuaridh Duncan
- Graham R. SmithGSGraham R. Smith
- Suzanne McGillSMSuzanne McGill
- Richard J.S. BurchmoreRBRichard J.S. Burchmore
- Denisa BogdanDBDenisa Bogdan
- Juan M. Jiménez-VacasJJJuan M. Jiménez-Vacas
- Jonathan WeltiJWJonathan Welti
Open Access
- 17 February 2026
- journal article
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 136 (7)
Abstract
Treatment of locally advanced and metastatic prostate cancer (PC) with androgen receptor–targeting (AR-targeting) therapies has limited durability, with disease eventually progressing to castrate-resistant PC (CRPC). Constitutively active AR splice variants (AR-Vs), such as AR-V7, play a key role in driving treatment resistance and disease progression. Importantly, the failure to attenuate AR-V function represents a major unmet clinical need, and as such, defining how AR-Vs are generated is likely to yield new therapeutic targets. Our knowledge of factors that mediate splicing of AR-V–encoding mRNAs remains limited. Here, we have employed an RNA-targeting CasRx approach to identify selective protein interactors of AR-V7 mRNA in PC. TRA2B and its ortholog, TRA2A, were identified as splicing regulators of AR transcripts that facilitate AR-V synthesis at the expense of full-length AR isoforms. TRA2B expression correlated with AR-V7 transcript in CRPC and attenuation of TRA2-mediated splicing diminished PC cell growth. Exploiting TRA2B function may therefore provide new therapeutic opportunities in advanced disease.Keywords
Funding Information
- Prostate Cancer UK (CEO13_2-002)
- Prostate Cancer Foundation (18CHAL06,20YOUN17)
- Cancer Research UK (CTRQQR-2021\100009)
- Experimental Cancer Medicine Centre (N/A)
- Wellcome Trust (219594/Z/19/Z)
- Cancer Research UK (C9380/A25138)
- Ken Bell Bursary and JGW Patterson Foundation (12/21 NU009331)
- Prostate Cancer Research (PCR-6955)
- National Institute for Health and Care Research (NIHR205032)
This publication has 76 references indexed in Scilit:
- Native RNA Immunoprecipitation (RIP) for Precise Detection and Quantification of Protein-Interacting RNA2023
- Gene Set Knowledge Discovery with EnrichrCurrent Protocols, 2021
- Prostate Cancer 2020: “The Times They Are a’Changing”Cancer Cell, 2020
- Therapeutic targeting of the androgen receptor (AR) and AR variants in prostate cancerAsian Journal of Urology, 2020
- Modulation of metabolic functions through Cas13d-mediated gene knockdown in liverProtein & Cell, 2020
- Molecular Mechanisms of Enzalutamide Resistance in Prostate CancerCurrent Molecular Biology Reports, 2017
- Developing new targeting strategy for androgen receptor variants in castration resistant prostate cancerInternational Journal of Cancer, 2017
- The RNA helicase DDX39B and its paralog DDX39A regulate androgen receptor splice variant AR-V7 generationBiochemical and Biophysical Research Communications, 2017
- Androgen receptor signaling in prostate cancerCancer and Metastasis Reviews, 2014
- Splicing Regulation in Drosophila Sex Determination2003